title: Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
abstract: Cancer patients and mice bearing tumors develop a progressive immunosuppression manifested by a decreased delayed-type hypersensitivity, decreased T-cell lytic activity, diminished production of lymphokines, and a reduced T-cell proliferative response. The mechanisms underlying these changes are incompletely understood. We recently reported the presence of marked alterations in signal transduction in T-cells from mice bearing long-term (28-day) tumours. We hypothesized that a soluble product produced by the tumor or resulting from the immune response to tumor might be responsible for inducing the changes in T-cells. Tumor-infiltrating lymphocytes from patients with renal cell carcinoma tested here showed, in 10 of 11 cases, a marked decrease in the expression of the T-cell receptor zeta chain and in p56lck tyrosine kinase. The presence of major alterations in the tumor-infiltrating lymphocytes with only minor changes in the peripheral blood leukocyte T-cells supports the notion that the defects are induced by exposure to tumor. These results suggest that tumor-infiltrating lymphocytes may be compromised in their antitumor efficacy in patients with renal cell cancer.
authors.affiliation: Department of Immunology, Cleveland Clinic Foundation.
authors.forename: J H
authors.initials: JH
authors.lastname: Finke
authors.forename: A H
authors.initials: AH
authors.lastname: Zea
authors.forename: J
authors.initials: J
authors.lastname: Stanley
authors.forename: D L
authors.initials: DL
authors.lastname: Longo
authors.forename: H
authors.initials: H
authors.lastname: Mizoguchi
authors.forename: R R
authors.initials: RR
authors.lastname: Tubbs
authors.forename: R H
authors.initials: RH
authors.lastname: Wiltrout
authors.forename: J J
authors.initials: JJ
authors.lastname: O'Shea
authors.forename: S
authors.initials: S
authors.lastname: Kudoh
authors.forename: E
authors.initials: E
authors.lastname: Klein
mesh_terms: D002292:Carcinoma, Renal Cell / Q000737:chemistry* / Q000276:immunology; D006801:Humans; D007680:Kidney Neoplasms / Q000737:chemistry* / Q000276:immunology; D008213:Lymphocyte Activation; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck); D016246:Lymphocytes, Tumor-Infiltrating / Q000737:chemistry* / Q000276:immunology; D008565:Membrane Proteins / Q000032:analysis*; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D011948:Receptors, Antigen, T-Cell / Q000032:analysis*
chemical_list: D008565:Membrane Proteins; D011518:Proto-Oncogene Proteins; D011948:Receptors, Antigen, T-Cell; C054979:antigen T cell receptor, zeta chain; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck)